A randomized, double-blinded placebo-controlled study found that the mean relapse rate of patients with RRMS or secondary progressive MS (SPMS) was significantly lower following treatment with IL-12 and IL-23 monoclonal antibodies30. Here, IL23A is linked to secondary progressive multiple sclerosis.